MS virus: This Pfizer vaccine gives hope


SwitzerlandOvercrowded children’s hospitals due to RS virus – this vaccine gives hope

More and more young children and infants in Switzerland have to be treated in hospital for the so-called respiratory syncytial virus (RSV). A vaccine should help now.

1 / 4

During the week, the number of RSV patients at Inselspital Bern rose from 24 to 39.

20 min/Michael Scherrer

Children's hospitals in Switzerland are overcrowded due to the RS virus.

Children’s hospitals in Switzerland are overcrowded due to the RS virus.

20 min / Marco Zangger

In some cases, patients even had to be airlifted to other hospitals.

In some cases, patients even had to be airlifted to other hospitals.

20 minutes / Janina Schenker

It’s about it

  • The RS virus causes annual epidemics in autumn and winter.

  • Infants and young children are particularly affected, but the virus is usually harmless to adults and older children.

  • A vaccine could now remedy the situation.

During the week, the number of patients with the disease at the Inselspital Bern increased Respiratory syncytial virus (RSV) from 24 to 39. “The peak of RSV has not yet been reached,” Christoph Aebi, head of the children’s clinic at the Inselspital in Bern, told Tamedia a week ago. That RS-Virus is responsible for most cases of acute bronchitis in infants and young children. For adults and older children, the virus is mostly harmless and causes “only” mild Cold symptoms such as a runny nose, cough or sore throat.

Now a new vaccine offers hope. Pfizer writes in a press release: “If approved, Pfizer’s RSV vaccine candidate could be the first available maternal vaccine to help prevent this common and potentially life-threatening respiratory illness in infants.” The test vaccine “RSVpreF” was well tolerated, with no safety concerns for vaccinated people and their newborns, the pharmaceutical giant continued.

High efficiency in newborns

“We are excited by these data because this is the first ever vaccine tested that has been shown to help protect newborns from severe RSV-related respiratory disease immediately after birth,” said Annaliesa Anderson, head of vaccine research and development at Pfizer.

In a phase 3 study, the vaccine was 82 percent effective against severe MS disease during the first three months of life in infants. Both mother and child reportedly tolerated the vaccine well.

You or cap someone you know seriously ill child?

For the mantle Accompanying families with seriously ill children and young adults

Intensive children, parentscleaning

offered his hand concern hotline Tel. 143

Don’t miss more news

With a daily update, you will be informed about your favorite topics and will not miss any other news about current world events.
Get the most important information every day straight to your mailbox.


Leave a Comment